<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342144</url>
  </required_header>
  <id_info>
    <org_study_id>P17-132</org_study_id>
    <nct_id>NCT03342144</nct_id>
  </id_info>
  <brief_title>Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting</brief_title>
  <official_title>Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational study to assess the effectiveness, health economic-relevant costs and
      patient reported outcomes in patients with Chronic lymphocytic leukemia (CLL) receiving
      venetoclax as prescribed at the discretion of the physician and in accordance with local
      clinical practice and label.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Best Overall Response Rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the percentage of participants achieving partial response (PR) and complete response with incomplete regeneration of bone marrow (CRi) and complete response (CR) according to physician's assessment to therapy with venetoclax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Administering Venetoclax</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients administering venetoclax throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Progression</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Disease progression as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients with OS where OS is defined as the number of days from the date of entry in the study to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percentage of patients with PFS where PFS is defined as the number of days from the date of entry in the study to the date of the first documented disease progression, start of a subsequent treatment regimen, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) measurement on plasma circulating tumor Deoxyribo nucleic acid (DNA) (Switzerland Only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>MRD is defined as less than 1 clonal lymphocyte per 10000 leukocytes in peripheral blood or bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Response (CR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Complete Response as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Response with Incomplete Regeneration of Bone Marrow (CRi)</measure>
    <time_frame>Up 24 months</time_frame>
    <description>Incomplete regeneration of bone marrow (CRi) as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Partial Response (PR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Partial response as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Progressive Disease</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Progressive disease as defined in the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Stable Disease (SD)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>SD is defined as percentage of all patients not having PD, but who do not meet the criteria for PR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using EORTC QLQ-C30 Scores</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ) developed to assess the quality of life of cancer patients. and is based on multi‐item and single‐item scales. The core questionnaire contains 5 functional scales, 3 symptom scales, 1 global health status scale, as well as 6 single‐item measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-CLL 16/17 Scores</measure>
    <time_frame>Up to 104 weeks</time_frame>
    <description>Quality of Life Questionnaire - Chronic Lymphocytic Leukemia (QLQ-CLL)16/17 is designed for patients with stage 0 to stage 4 chronic lymphocytic leukemia. It is used to assess 5 domains of health-related quality of life important in CLL: fatigue, side effects and symptoms of disease, infection and social activities or future illness‐related concerns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life 5 Dimensions (EQ-5D-5L) including visual analogue scale (VAS)</measure>
    <time_frame>Up 24 months</time_frame>
    <description>The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life. EQ‐5D‐5L questionnaire consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ‐5D‐5L questionnaire plus a VAS will be used to assess general health in 5 dimensions (mobility, self‐care, usual activities, pain/discomfort anxiety/depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management of Venetoclax Therapy</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Management of venetoclax therapy includes time from blood sampling to laboratory result availability, changes in laboratory values, occurence of tumor lysis syndrome and possible interventions, length and reason for hospitalizations, duration of IV hydration, therapy modifications, supportive therapies other criteria described in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Utilization (HRU) per year</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Health Resource Utilization (HRU) per year will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clonal evolution and eradication of Tumor Protein p53 (TP53) mutated clones associated with treatment in relation to MRD negativity (Switzerland Only)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Clonal evolution and eradication of TP53 mutated clones associated with treatment in relation to MRD negativity is evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of MRD Assessment</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Value of MRD assessment by flow cytometry compared to comprehensive MRD assessment including flow cytometry plus NGS in peripheral blood as described in Annex II (Switzerland only).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Participants Receiving Venetoclax</arm_group_label>
    <description>Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants Receiving Venetoclax + Rituximab</arm_group_label>
    <description>Participants with CLL receiving venetoclax in combination with rituximab.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphocytic leukemia (CLL) administering venetoclax per the local
        label.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with chronic lymphocytic leukemia (CLL) administering venetoclax and who meets
             the following conditions as specified in the label for venetoclax:

          -  Venetoclax monotherapy for the treatment of CLL in the presence of deletion chromosome
             17 (del[17p]) or tumor protein p53 (TP53) mutation in adult patients, who are
             unsuitable for or have failed to a B‐cell receptor pathway inhibitor.

          -  Venetoclax monotherapy for the treatment of CLL in the absence of del(17p) or TP53
             mutation in adult patients, who have failed both chemoimmunotherapy and a B‐cell
             receptor pathway inhibitor.

          -  Venetoclax in combination with rituximab for the treatment of adult patients with CLL
             who have received at least one prior therapy.

        Exclusion Criteria:

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Huelsenbeck</last_name>
    <phone>+49 611-1720-3036</phone>
    <email>johannes.huelsenbeck@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjoern Tews</last_name>
    <email>bjoern.tews@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital St. Polten /ID# 221152</name>
      <address>
        <city>St. Pölten</city>
        <state>Niederoesterreich</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik für Innere Medizin, Klinische Abteilung für Hämatologie, Graz /ID# 221155</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Innere Medizin 1 /ID# 221153</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus der WGKK /ID# 221151</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis /ID# 201545</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar-Klinikum /ID# 208176</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum (MVZ) /ID# 201548</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg /ID# 204125</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Hornberger &amp; Kollegen /ID# 202613</name>
      <address>
        <city>Bad Reichenhall</city>
        <state>Bayern</state>
        <zip>83435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie am Segelfliegerdamm /ID# 202603</name>
      <address>
        <city>Berlin</city>
        <state>Bayern</state>
        <zip>12487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie Hof /ID# 201531</name>
      <address>
        <city>Hof</city>
        <state>Bayern</state>
        <zip>95028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Stauch /ID# 202611</name>
      <address>
        <city>Kronach</city>
        <state>Bayern</state>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Vehling-Kaiser /ID# 202614</name>
      <address>
        <city>Landshut</city>
        <state>Bayern</state>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologie /ID# 205236</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Kröber/Stosiek /ID# 206729</name>
      <address>
        <city>Ratisbon</city>
        <state>Berlin</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kreher /ID# 202604</name>
      <address>
        <city>Bad Liebenwerda</city>
        <state>Brandenburg</state>
        <zip>04924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Kiehl/Stein /ID# 210052</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <state>Brandenburg</state>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ f. Blut- u.Krebserkrankungen /ID# 206704</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum für Hämatologie /ID# 206701</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Dres. Cordes &amp; Partner /ID# 202598</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Tebbe/Mayer /ID# 206730</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Onkol. Kooperation Harz /ID# 201550</name>
      <address>
        <city>Goslar</city>
        <state>Niedersachsen</state>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OAZ Hannover /ID# 201538</name>
      <address>
        <city>Hanover</city>
        <state>Niedersachsen</state>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkolologische Praxis Oldenburg /ID# 202607</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ der Paracelsus-Klinik /ID# 201541</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med. Studiengesellschaft Nord West GmbH /ID# 201535</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Plewe/Losem /ID# 202606</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologie und Onkologie /ID# 205247</name>
      <address>
        <city>Kaiserslautern</city>
        <state>Rheinland-Pfalz</state>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden /ID# 202599</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter /ID# 201532</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ am Klinikum Glauchau /ID# 206697</name>
      <address>
        <city>Glauchau</city>
        <state>Sachsen</state>
        <zip>08371</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Friedrich-Ebert-Krankenhaus GmbH /ID# 206206</name>
      <address>
        <city>Neumünster</city>
        <state>Schleswig-Holstein</state>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drs. Brudler, Heinrich und Ban /ID# 200950</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Klinikum Mittelbaden GmbH /ID# 206207</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis /ID# 200953</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Prange-Krex/Mohm /ID# 210049</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktprax /ID# 200949</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Hoechst /ID# 210048</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis f. Onkol. &amp; Hämatologie /ID# 206999</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologie GmbH /ID# 212376</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkomedic GbR /ID# 218354</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie Lerchenfeld /ID# 205237</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis /ID# 205239</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm /ID# 206703</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein GmbH /ID# 210046</name>
      <address>
        <city>Idar-oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luebecker Oncology Practice /ID# 200952</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwaebisch Gm /ID# 201518</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klaproth/Cura /ID# 216413</name>
      <address>
        <city>Neunkirchen</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bruederkrankenhaus St. Josef P /ID# 202600</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis GbR /ID# 206705</name>
      <address>
        <city>Porta Westfalica</city>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Decker/Lakner/Leithäuser /ID# 206208</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ am Schlossgarten GmbH /ID# 210043</name>
      <address>
        <city>Schwetzingen</city>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonieklinikum Schwäbisch Hall /ID# 206205</name>
      <address>
        <city>Schwäbisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau /ID# 210034</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni /ID# 208782</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universitaetsklinik /ID# 210031</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital /ID# 210029</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Muensterlingen /ID# 210035</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur /ID# 211068</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Leukemia</keyword>
  <keyword>venetoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

